Benefits and Safety of Tirofiban Among Acute Coronary Syndrome Patients With Mild to Moderate Renal Insufficiency: Results From the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial

Circulation - United States
doi 10.1161/01.cir.0000016359.94919.16
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)


Related search